Chemical Nameopicapone
Dosage FormCapsules (oral; 25 mg, 50 mg)
Drug ClassInhibitors
CompanyNeurocrine Biosciences, Inc.
Approval Year2020


  • Indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ongentys (opicapone) Prescribing Information.2020Neurocrine Biosciences, Inc., San Diego, CA